180 related articles for article (PubMed ID: 22976197)
1. Bispecific antibody derivatives with restricted binding functionalities that are activated by proteolytic processing.
Metz S; Panke C; Haas AK; Schanzer J; Lau W; Croasdale R; Hoffmann E; Schneider B; Auer J; Gassner C; Bossenmaier B; Umana P; Sustmann C; Brinkmann U
Protein Eng Des Sel; 2012 Oct; 25(10):571-80. PubMed ID: 22976197
[TBL] [Abstract][Full Text] [Related]
2. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I
Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485
[TBL] [Abstract][Full Text] [Related]
3. A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.
Schanzer JM; Wartha K; Croasdale R; Moser S; Künkele KP; Ries C; Scheuer W; Duerr H; Pompiati S; Pollman J; Stracke J; Lau W; Ries S; Brinkmann U; Klein C; Umana P
J Biol Chem; 2014 Jul; 289(27):18693-706. PubMed ID: 24841203
[TBL] [Abstract][Full Text] [Related]
4. A modular IgG-scFv bispecific antibody topology.
Orcutt KD; Ackerman ME; Cieslewicz M; Quiroz E; Slusarczyk AL; Frangioni JV; Wittrup KD
Protein Eng Des Sel; 2010 Apr; 23(4):221-8. PubMed ID: 20019028
[TBL] [Abstract][Full Text] [Related]
5. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
Lu D; Jimenez X; Witte L; Zhu Z
Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
[TBL] [Abstract][Full Text] [Related]
6. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
[TBL] [Abstract][Full Text] [Related]
7. Expression of a bispecific dsFv-dsFv' antibody fragment in Escherichia coli.
Schmiedl A; Breitling F; Dübel S
Protein Eng; 2000 Oct; 13(10):725-34. PubMed ID: 11112512
[TBL] [Abstract][Full Text] [Related]
8. Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.
Klein C; Sustmann C; Thomas M; Stubenrauch K; Croasdale R; Schanzer J; Brinkmann U; Kettenberger H; Regula JT; Schaefer W
MAbs; 2012; 4(6):653-63. PubMed ID: 22925968
[TBL] [Abstract][Full Text] [Related]
9. Nanocell targeting using engineered bispecific antibodies.
Taylor K; Howard CB; Jones ML; Sedliarou I; MacDiarmid J; Brahmbhatt H; Munro TP; Mahler SM
MAbs; 2015; 7(1):53-65. PubMed ID: 25523746
[TBL] [Abstract][Full Text] [Related]
10. Stability engineering of scFvs for the development of bispecific and multivalent antibodies.
Miller BR; Demarest SJ; Lugovskoy A; Huang F; Wu X; Snyder WB; Croner LJ; Wang N; Amatucci A; Michaelson JS; Glaser SM
Protein Eng Des Sel; 2010 Jul; 23(7):549-57. PubMed ID: 20457695
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibody derivatives based on full-length IgG formats.
Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
[TBL] [Abstract][Full Text] [Related]
12. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
13. A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G
De Nardis C; Hendriks LJA; Poirier E; Arvinte T; Gros P; Bakker ABH; de Kruif J
J Biol Chem; 2017 Sep; 292(35):14706-14717. PubMed ID: 28655766
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies.
Schaefer W; Regula JT; Bähner M; Schanzer J; Croasdale R; Dürr H; Gassner C; Georges G; Kettenberger H; Imhof-Jung S; Schwaiger M; Stubenrauch KG; Sustmann C; Thomas M; Scheuer W; Klein C
Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11187-92. PubMed ID: 21690412
[TBL] [Abstract][Full Text] [Related]
15. TriFabs--Trivalent IgG-Shaped Bispecific Antibody Derivatives: Design, Generation, Characterization and Application for Targeted Payload Delivery.
Mayer K; Baumann AL; Grote M; Seeber S; Kettenberger H; Breuer S; Killian T; Schäfer W; Brinkmann U
Int J Mol Sci; 2015 Nov; 16(11):27497-507. PubMed ID: 26593903
[TBL] [Abstract][Full Text] [Related]
16. Characterization and analysis of scFv-IgG bispecific antibody size variants.
Cao M; Wang C; Chung WK; Motabar D; Wang J; Christian E; Lin S; Hunter A; Wang X; Liu D
MAbs; 2018; 10(8):1236-1247. PubMed ID: 30130449
[TBL] [Abstract][Full Text] [Related]
17. Rapid optimization and prototyping for therapeutic antibody-like molecules.
Xu L; Kohli N; Rennard R; Jiao Y; Razlog M; Zhang K; Baum J; Johnson B; Tang J; Schoeberl B; Fitzgerald J; Nielsen U; Lugovskoy AA
MAbs; 2013; 5(2):237-54. PubMed ID: 23392215
[TBL] [Abstract][Full Text] [Related]
18. Generation and characterization of monospecific and bispecific hexavalent trimerbodies.
Blanco-Toribio A; Sainz-Pastor N; Álvarez-Cienfuegos A; Merino N; Cuesta ÁM; Sánchez-Martín D; Bonet J; Santos-Valle P; Sanz L; Oliva B; Blanco FJ; Álvarez-Vallina L
MAbs; 2013; 5(1):70-9. PubMed ID: 23221741
[TBL] [Abstract][Full Text] [Related]
19. Rational design and generation of recombinant control reagents for bispecific antibodies through CDR mutagenesis.
Choi BD; Gedeon PC; Kuan CT; Sanchez-Perez L; Archer GE; Bigner DD; Sampson JH
J Immunol Methods; 2013 Sep; 395(1-2):14-20. PubMed ID: 23806556
[TBL] [Abstract][Full Text] [Related]
20. Structural differences between glycosylated, disulfide-linked heterodimeric Knob-into-Hole Fc fragment and its homodimeric Knob-Knob and Hole-Hole side products.
Kuglstatter A; Stihle M; Neumann C; Müller C; Schaefer W; Klein C; Benz J;
Protein Eng Des Sel; 2017 Sep; 30(9):649-656. PubMed ID: 28985438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
